Galectin Therapeutics Inc GALT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Galectin Therapeutics to Participate in the H.C. Wainwright MASH Conference
-
Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
-
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update
-
Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 14
Comparables
Valuation
|
Metric
|
GALT
|
FULC
|
CTNM
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 0.86 | 2.23 |
Price/Sales | — | 2.90 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
GALT
FULC
CTNM
Financial Strength
|
Metric
|
GALT
|
FULC
|
CTNM
|
|---|---|---|---|
Quick Ratio | 1.75 | 21.84 | 58.48 |
Current Ratio | 1.87 | 22.07 | 58.92 |
Interest Coverage | −10.14 | — | — |
Quick Ratio
GALT
FULC
CTNM
Profitability
|
Metric
|
GALT
|
FULC
|
CTNM
|
|---|---|---|---|
Return on Assets (Normalized) | −165.12% | −1.76% | −18.15% |
Return on Equity (Normalized) | — | −1.91% | −871.68% |
Return on Invested Capital (Normalized) | −345.36% | −1.83% | −892.99% |
Return on Assets
GALT
FULC
CTNM
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Qvrsddfbc | Hys | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Hspwgvlm | Zckkbqc | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Mrdqhvbg | Cskdcy | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Msfgksyf | Zmgyb | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Xpvqknmp | Gfx | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Gkqhgmfg | Cxx | $28.1 Bil | |||
| Moderna Inc
MRNA
| Lkjnbwlw | Rspt | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Xynstwnd | Whqlv | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Dgxbkqtlf | Cpjhftz | $13.4 Bil | |||
| Incyte Corp
INCY
| Dpxrxvfb | Lmxpkyz | $12.7 Bil |
United States